Inspiro Medical

Inspiro Medical was acquired by OPKO Health, Inc. in April 2014.

Inspiro Medical Inspiromatic™ presents a breakthrough dry powder inhaler (DPI) that overcomes the drawbacks of current inhalers.

The Product

Inspiro’s proprietary DPI is the first device to combine an active dry powder fluidization mechanism that works at low inhalation flow rates with a unique real-time feedback control and data logger indicating proper inhalation technique and follow-up.

Inspiromatic assures optimal drug delivery. Young children and the elderly will particularly benefit from the advantages of Inspiro’s dry powder inhalation.

The Team

  • Nimrod Kaufmann, CEO: Extensive experience in the medical device industry, taking products from initial concept through manufacturing; B.Sc., mechanical engineering, Ben-Gurion University of the Negev
  • Guy Steuer, M.D., Inventor: Senior physician and pediatric pulmonologist, Schneider Children’s Medical Center of Israel; lecturer, Tel Aviv University; involved in development of numerous medical devices; consulted to Tree of Life Pharma and Stata Venture Partners, among others; M.D. and B.Sc., Hebrew University of Jerusalem; pulmonology fellowship, University of Pittsburgh

Status & Achievements

Founded: 2010
Investor: The Trendlines Group
IP: National phase
In the media: Inspiro Medical acquired by OPKO

  • Q2 2014 acquired by OPKO
  • Q4 2013 pre-marketing device
  • Q2 2013 completed FIM trial

Background & Market

Currently available inhalers, including metered dose inhalers (MDIs), DPIs, and nebulizers, are often less than effective in delivering the necessary medication.

The optimal delivery device aims for the most efficient and effective deposition of aerosol medication, accounting for drug particle/droplet size and the patient’s ability to understand and use the device.

MDIs require hand-breath coordination. DPIs are breath actuated and may require forceful inhalation. Many patients do not use these devices properly because of the complexities. With nebulizers, treatment time is relatively long, setup is cumbersome, and the apparatus is usually bulky and inconvenient.

The market needs an innovative aerosol delivery device that is convenient and easy to use; delivers medication effectively; and suits adults, children, the elderly, and the seriously ill.

Inspiro’s smart DPI designed for the treatment of pulmonary diseases such as asthma and chronic obstructive pulmonary disease (COPD). According to the World Health Organization, an estimated 300 million people worldwide suffer from asthma, with 250,000 deaths attributed to the disease annually. COPD affects 210 million people worldwide and is projected to be the third leading cause of death by 2020.

Inspiro logo

Font Resize